Crystal's MCW Coder Hub🔬 CPT Code 43198 — Esophagoscopy, Rigid or Flexible Transnasal; with Biopsy, Single or Multiple
Quick Reference
Global Period: 000 days | wRVU: 2.00 | Assistant Payable: ❌ No | Co-Surgeon: ❌ No | Category: Surgery – Digestive System / Esophagus | Setting: Office / ASC / Outpatient | Access Route: Transnasal | Key Feature: Forceps tissue biopsy (single or multiple specimens)
📋 Official CPT Description
CPT 43198 — Esophagoscopy, rigid or flexible transnasal; with biopsy, single or multiple
This code describes a transnasal esophagoscopy (TNE) — performed by passing an ultra-thin flexible (or rigid) endoscope through the nasal cavity → nasopharynx → hypopharynx → esophagus → gastroesophageal junction (GEJ) — that includes forceps tissue biopsy of esophageal mucosa, obtained as single or multiple specimens during the same endoscopic session. 43198 is the biopsy-inclusive companion code to 43197 (diagnostic TNE without biopsy), and represents the more comprehensive service when tissue sampling is required for histopathologic analysis.
The distinction between 43197 and 43198 rests entirely on whether forceps biopsy is performed:
- 43197 = Transnasal esophagoscopy ± brushing/washing → NO forceps biopsy
- 43198 = Transnasal esophagoscopy ± brushing/washing → WITH forceps biopsy (one or many specimens)
Note
🧠 Detailed Clinical Description
What Is Transnasal Esophagoscopy with Biopsy?
Transnasal esophagoscopy with biopsy (43198) is the office-based or ambulatory endoscopic examination of the esophagus via the nasal route — combined with direct forceps tissue sampling of one or more abnormal or suspicious mucosal sites. The procedure combines the advantages of the transnasal approach (no sedation, office-based, laryngeal visualization, immediate return to activities) with the diagnostic power of histopathologic tissue confirmation — the gold standard for definitive esophageal mucosal diagnosis.
Scope Technology and Working Channel Requirements
Unlike 43197 (diagnostic only), 43198 requires a scope with a working channel large enough to accommodate biopsy forceps:
| Scope Type | Outer Diameter | Working Channel | Biopsy Capability |
|---|---|---|---|
| Ultra-thin flexible (standard) | 3.2–4.9 mm | 2.0 mm | ✅ 1.8 mm biopsy forceps — adequate for standard biopsies |
| Distal chip ultra-thin (high definition) | 5.1–5.9 mm | 2.0–2.4 mm | ✅ Superior optics; 1.8–2.0 mm forceps |
| Standard thin flexible | 6.0–7.5 mm | 2.2–2.8 mm | ✅ Full-size biopsy forceps; near-standard specimen quality |
| Rigid transnasal | 4.0–5.0 mm | Variable | Limited — tissue forceps required; technically challenging |
Biopsy Specimen Size Consideration
TNE biopsy specimens obtained through a 2.0 mm working channel with 1.8 mm cup biopsy forceps are smaller than those obtained through a standard transoral EGD scope (2.8–3.7 mm working channel). This is clinically relevant for:
- Barrett’s esophagus surveillance — smaller specimen may limit Prague classification precision; Seattle protocol (4-quadrant biopsies every 1–2 cm) is technically challenging but achievable
- Eosinophilic esophagitis (EoE) — adequate specimen size for eosinophil counting (≥15 eos/HPF threshold) generally achievable; multiple biopsies from proximal and distal esophagus recommended
- Malignant lesions — biopsy may be sufficient for diagnosis but large lesions may benefit from standard EGD for larger specimen or EUS-guided sampling
Document scope type, working channel size, and number/location of biopsies in the procedure report.
”Single or Multiple” Biopsy — One Code Regardless of Number
A critical coding principle for 43198: the code descriptor states “with biopsy, single or multiple” — this means 43198 is reported ONCE regardless of how many biopsy specimens are obtained during a single TNE session. The following scenarios all map to a single unit of 43198:
| Scenario | Number of Biopsy Specimens | Code |
|---|---|---|
| One biopsy of distal esophageal nodule | 1 specimen | 43198 × 1 |
| Four-quadrant biopsies of Barrett’s segment | 4–8 specimens | 43198 × 1 |
| Biopsies at 20 cm, 30 cm, and 38 cm (three sites) | 3 specimens | 43198 × 1 |
| Seattle protocol — 16 specimens, 4 levels | 16 specimens | 43198 × 1 |
Do NOT Bill Multiple Units of 43198
Billing 43198 × 2 or more units for multiple biopsy specimens taken in a single TNE session is a NCCI violation and an upcoding error. The “single or multiple” language in the descriptor is explicit — the code is designed to encompass all biopsy specimens obtained during one endoscopic session, regardless of number or site. A single unit of 43198 is the correct billing regardless of specimen count.
The Biopsy Procedure — Technique Details
Biopsy during 43198 is performed using cup biopsy forceps passed through the working channel of the transnasal scope:
- Target identification — Abnormal mucosa visualized under direct endoscopic view (color change, texture irregularity, nodularity, erosion, plaque)
- Forceps introduction — Biopsy forceps introduced through the working channel under direct vision
- Positioning — Forceps advanced past the scope tip; positioned perpendicular or tangential to the mucosal target
- Specimen capture — Forceps cups opened; advanced into mucosa; cups closed; gentle traction applied to obtain mucosal core specimen
- Retrieval — Forceps withdrawn through working channel; specimen transferred to formalin
- Repeat — Steps 2–5 repeated for each additional biopsy site
- Hemostasis — Minor bleeding from biopsy sites typically resolves spontaneously; electrocautery or epinephrine injection rarely required for TNE biopsies
- Documentation — Biopsy site(s) recorded with distance from nares (cm) and clock position; number of specimens; specimen jar labeling; correlation with endoscopic finding
Relationship Between 43197 and 43198 in Clinical Practice
In real-world ENT/gastroenterology office practice, the decision to perform biopsy (upgrading from 43197 to 43198) is often made intraoperatively based on mucosal findings discovered during the esophagoscopy:
| Pre-procedure plan | Intraoperative finding | Correct code |
|---|---|---|
| Diagnostic TNE planned | Normal mucosa — no biopsy | 43197 |
| Diagnostic TNE planned | Abnormal mucosa discovered — biopsy taken | 43198 |
| Biopsy TNE planned | Biopsy obtained as planned | 43198 |
| Biopsy TNE planned | Patient intolerant — scope removed before biopsy | 43197 or 43197 + 52 |
Intraoperative Upgrade — Code What Was Actually Performed
If a TNE is planned as diagnostic (43197) but biopsy is taken intraoperatively due to unexpected mucosal findings, report 43198 — not 43197. The code must reflect the actual service rendered, not the pre-procedure plan. Document the unexpected finding and clinical decision to biopsy in the procedure report.
Clinical Indications for 43198
43198 is indicated when tissue diagnosis is required as part of the esophagoscopic evaluation:
| Clinical Indication | Biopsy Target | Histopathologic Goal |
|---|---|---|
| Barrett’s esophagus confirmation | Salmon-colored columnar mucosa at/above GEJ | Confirm intestinal metaplasia; assess for dysplasia |
| Barrett’s esophagus surveillance | Known Barrett’s segment — systematic sampling | Detect progression to dysplasia or adenocarcinoma |
| Eosinophilic esophagitis (EoE) diagnosis | Proximal and distal esophagus — systematic biopsies | Eosinophil count ≥15/HPF; exclude GERD etiology |
| EoE treatment response monitoring | Known EoE segment post-treatment | Eosinophil count reduction confirmation |
| Erosive esophagitis — atypical or refractory | Erosive/ulcerative area | Exclude malignancy, infection, drug-induced esophagitis |
| Esophageal mass or nodule | Mass lesion | Tissue diagnosis — SCC, adenocarcinoma, GIST, carcinoid |
| Candidal esophagitis confirmation | White plaques | Confirm Candida (yeast forms, pseudohyphae on H&E or PAS) |
| CMV/HSV esophagitis | Ulcer base/margin | Intranuclear inclusions; immunohistochemistry for virus |
| Esophageal stricture — malignancy concern | Stricture mucosa | Exclude adenocarcinoma or SCC causing functional stricture |
| Pill esophagitis | Erosion/ulcer at level of medication lodging | Confirm drug-induced injury; exclude other etiology |
| Post-ablation Barrett’s surveillance | Post-RFA or cryotherapy treatment zone | Confirm complete eradication of intestinal metaplasia |
| Submucosal lesion sampling | Submucosal bulge | Limited yield (deep biopsy with standard forceps); EUS preferred for deep lesions |
| Esophageal inlet patch (ectopic gastric mucosa) | Proximal esophagus pink patch | Confirm heterotopic gastric mucosa — associated with globus |
| Glycogenic acanthosis | Whitish plaques mid-esophagus | Confirm benign glycogenic acanthosis vs. candidiasis |
Seattle Protocol — Barrett’s Biopsy Under 43198
The Seattle protocol for Barrett’s esophagus surveillance — the standard-of-care systematic biopsy strategy — involves:
- 4-quadrant biopsies every 1–2 cm throughout the Barrett’s segment
- Targeted biopsies of any visible mucosal irregularity, nodule, or area of concern
Example: A patient with 4 cm Barrett’s segment → biopsies at 4 positions per level × 4 levels = 16 specimens → all reported under one unit of 43198.
Seattle Protocol Feasibility via TNE
The Seattle protocol is technically achievable via TNE but is more challenging than via standard EGD due to:
- Smaller biopsy forceps cup size (less tissue per bite)
- Longer time to obtain multiple specimens (repeated forceps passes)
- Patient tolerance (longer procedure time without sedation)
In practice, TNE-based Barrett’s surveillance often uses a modified protocol — fewer biopsies per level or targeted-only approach — particularly when no visible lesion is present and the primary goal is dysplasia surveillance in short-segment Barrett’s. Document the specific protocol used in the procedure report.
Sedation Profile — Same as 43197
Like 43197, 43198 is typically performed without IV sedation:
| Anesthesia Type | Typical Use |
|---|---|
| Topical nasal + pharyngeal anesthetic | Standard — oxymetazoline + lidocaine spray |
| Topical esophageal lidocaine | Through working channel for distal sensitivity |
| No systemic anesthesia | Most common approach |
| IV conscious sedation | Occasionally — anxious patients; not routine |
| General anesthesia | Rarely — specific OR-based scenarios |
Info
The post-biopsy observation period is brief — patients typically return to activities within 30–60 minutes of the topical anesthesia wearing off. No driving restriction is required in the absence of sedation.
Complete Surgical Steps for 43198
- Preoperative preparation — Informed consent including biopsy risks (bleeding, perforation — rare with TNE); review of indications; NPO status typically not required for office TNE
- Nasal preparation — Bilateral oxymetazoline spray; assess nasal patency; select more patent nasal passage
- Topical anesthesia — Lidocaine 4% spray to nasal cavity, nasopharynx, and hypopharynx; benzocaine spray to posterior pharynx; allow 2–3 minutes for effect
- Scope preparation — Working channel confirmed patent; biopsy forceps loaded or available; white balance and focus confirmed; video recording initiated
- Transnasal scope introduction — Scope advanced along nasal floor through nasal cavity to nasopharynx
- Hypopharyngeal and laryngeal assessment — Piriform sinuses, epiglottis, arytenoids, true vocal cords documented during scope passage
- UES negotiation — Patient instructed to swallow; scope passed through cricopharyngeus into cervical esophagus
- Systematic esophageal examination — All esophageal segments visualized; mucosal pattern, color, vascular pattern, luminal diameter documented
- GEJ assessment — Z-line position, hiatal hernia, distal mucosal changes documented
- Biopsy target identification — Abnormal mucosal areas identified and photographically documented prior to biopsy
- Biopsy forceps introduction — Forceps passed through working channel under direct vision
- Tissue sampling — Forceps cups opened, advanced, and closed on target mucosa; specimen retrieved; placed in labeled formalin jar; repeated as clinically indicated at additional sites
- Post-biopsy hemostasis assessment — Biopsy sites inspected for bleeding; minor oozing expected and self-limited; significant bleeding treated if needed
- Systematic scope withdrawal — Esophageal mucosa re-examined on withdrawal; laryngeal/pharyngeal re-assessment
- Specimen handling — All biopsy jars labeled with site (distance from nares, location); pathology requisition completed with clinical history and specific site designation
- Post-procedure instructions — Soft diet for remainder of day (precaution); return precautions for signs of bleeding, chest pain, or fever
💰 Reimbursement & RVU Profile
| Component | Value |
|---|---|
| Work RVU (wRVU) | 2.00 CMS MPFS 2025 |
| Global Period | 000 days |
| Assistant Surgeon Payable | ❌ No (Indicator: 0) |
| Co-Surgeon Payable | ❌ No |
| Team Surgery | ❌ No |
| Facility RVU | ✅ Yes |
| Non-Facility RVU | ✅ Yes (office-based — higher total RVU) |
| Multiple Procedure Indicator | 2 (standard reduction applies) |
| Bilateral Surgery Indicator | 0 |
Facility vs. Non-Facility RVU — 43198 in Office Practice
Like 43197, 43198 has both facility and non-facility RVU values — reflecting its predominant use as an office-based procedure (POS 11). The non-facility total RVU is substantially higher because the physician practice absorbs the cost of equipment, supplies, scope maintenance, and staff that would otherwise be covered by the facility.
Setting POS Code Approx. Total RVU Office (non-facility) 11 ~4.75 (higher — includes full PE RVU) Facility (hospital/ASC) 21, 22, 24 ~2.45 (lower — facility absorbs PE) An ENT or gastroenterology practice that performs 43198 in the office setting — rather than referring to a facility-based endoscopy suite — captures the full non-facility RVU, which meaningfully improves per-procedure reimbursement. This is a key economic driver for investment in office-based TNE programs.
wRVU Comparison — TNE and Esophagoscopy Family
Code wRVU Procedure 43197 1.26 Transnasal esophagoscopy, diagnostic (no biopsy) 43198 2.00 Transnasal esophagoscopy, with biopsy (this code) 43200 ~2.60 Transoral flexible esophagoscopy, diagnostic 43202 ~3.17 Transoral flexible esophagoscopy, with biopsy 43235 ~3.50 Upper GI endoscopy (EGD), diagnostic 43239 ~4.43 EGD with biopsy The ~0.74 wRVU premium of 43198 over 43197 reflects the additional technical complexity and time required for forceps biopsy — working channel navigation, forceps handling, specimen transfer, site-by-site documentation, and hemostasis assessment. When multiple biopsy specimens are obtained (e.g., Seattle protocol), the additional clinical work is substantial but not separately compensated — the code pays the same regardless of specimen count.
✅ Included Services (Bundled into 43198)
The following are not separately reportable when performed as integral components of 43198:
- Complete transnasal esophagoscopy — nasal passage, nasopharynx, hypopharynx, larynx, all esophageal segments, GEJ
- Laryngeal and hypopharyngeal visualization incidental to scope passage
- Topical nasal and pharyngeal anesthesia administration
- Nasal decongestant spray (oxymetazoline) application
- Routine photography and video documentation of all findings
- Specimen collection by brushing — when performed alongside biopsy (brushing bundled into 43198)
- Specimen collection by washing/lavage — when performed alongside biopsy (bundled)
- Biopsy — single or multiple specimens — all forceps biopsies in one session (the defining service)
- Biopsy forceps introduction, deployment, and retrieval
- Specimen transfer to formalin and labeling
- Post-biopsy hemostasis assessment (routine)
- Scope withdrawal with systematic mucosal re-examination
- Standard procedure report documentation
- Brief post-procedure observation (office setting)
- Routine post-procedure patient instructions
❌ Excludes / Separately Reportable Services
The following may be billed separately when clearly documented as distinct services:
| Separate Service | Code |
|---|---|
| Transnasal esophagoscopy, diagnostic only (no biopsy taken) | 43197 |
| Flexible transoral esophagoscopy, diagnostic | 43200 |
| Flexible transoral esophagoscopy with biopsy | 43202 |
| Upper GI endoscopy (EGD) diagnostic | 43235 |
| EGD with biopsy | 43239 |
| Nasopharyngoscopy (nasal/pharyngeal exam only) | 92511 |
| Flexible laryngoscopy, diagnostic | 31575 |
| Flexible laryngoscopy with biopsy | 31576 |
| Flexible laryngoscopy with stroboscopy | 31579 |
| Fiberoptic endoscopic evaluation of swallowing (FEES) | 92612, 92613 |
| Esophageal dilation (when separately performed) | 43450, 43453 |
| Esophageal foreign body removal | 43215 |
| Esophageal polypectomy | 43217 |
| Radiofrequency ablation of esophagus (Barrett’s treatment) | 43228 |
| Esophageal stent placement | 43212 |
| Esophageal ultrasound (EUS) | 43231, 43232 |
| Esophageal manometry | 91010, 91013 |
| Ambulatory pH / impedance monitoring | 91034–91038 |
| Moderate sedation (if separately provided by different clinician) | 99152, 99153 |
| Pathology evaluation of biopsy specimens (histopathology) | Pathology codes — billed by pathologist/lab |
| Cytopathology evaluation of brushing specimens | 88104 — billed by pathologist |
| Radiologic supervision and interpretation (if fluoroscopy used) | 74360 |
| Return to procedure suite for related procedure | 43198 with modifier 78 |
Pathology Is Always Separately Billable — By the Pathologist
The histopathologic evaluation of biopsy specimens obtained during 43198 is billed separately by the pathologist or laboratory — not by the endoscopist. Common pathology CPT codes generated by 43198 biopsies:
Pathology Code Description 88305 Level IV surgical pathology; gross and microscopic examination (most common for esophageal biopsies — includes Barrett’s, esophagitis, EoE) 88307 Level V surgical pathology (complex specimens — malignancy with special studies) 88104 Cytopathology, fluids, washings, or brushings (if brushing cytology also performed) 88342 Immunohistochemistry (p53, CDX2, p16 for Barrett’s; eosinophil peroxidase for EoE; viral IHC) The endoscopist performing 43198 bills 43198 only — not the pathology codes. Pathology is always a separate, independently billable service by the interpreting pathologist.
When TNE is performed transnasal and a laryngeal biopsy (vocal cord, arytenoid, epiglottis) is obtained in addition to an esophageal biopsy, the laryngeal biopsy may be separately coded as 31576 (flexible laryngoscopy with biopsy). However:
- The laryngeal biopsy must be independently indicated and at a distinct anatomical site from the esophageal biopsy
- Verify NCCI bundling — 31576 and 43198 may be subject to column 1/column 2 editing
- Apply modifier 59 and document separate indications, separate target tissues, and separate specimens for each biopsy site (laryngeal vs. esophageal)
- Many payers will deny 31576 alongside 43198 as bundled — verify before billing both
🔬 43197 vs. 43198 — Definitive Comparison
The Complete Distinction
| Feature | 43197 | 43198 |
|---|---|---|
| Procedure type | Diagnostic TNE | TNE with tissue biopsy |
| Scope access | Transnasal | Transnasal |
| Brushing/washing | ✅ Included when performed | ✅ Included when performed |
| Forceps biopsy | ❌ None | ✅ Yes — 1 or more specimens |
| Histopathology generated | No (cytology only if brushing done) | ✅ Yes — formalin-fixed tissue |
| Working channel required | ✅ Yes (for brushing) | ✅ Yes (for forceps) |
| wRVU | 1.26 | 2.00 |
| Pathology codes generated | 88104 (cytology) if brushing | 88305/88307 (surgical pathology) |
| Clinical determinant | Surveillance / evaluation / no tissue needed | Abnormal mucosa / tissue confirmation needed |
| Upgrade from 43197 possible? | — | ✅ Yes — if biopsy taken after scope insertion |
| Can be billed with 43198? | ❌ No — bundled | — |
🏷️ Applicable Modifiers
| Modifier | Description | When to Use |
|---|---|---|
| -51 | Multiple procedures | When 43198 is performed alongside another distinct procedure in the same session — e.g., separately indicated laryngoscopy with biopsy (31576); esophageal dilation (43220); append to lesser-valued code |
| -59 | Distinct procedural service | To unbundle a separately identifiable service at a distinct anatomical site — e.g., laryngeal biopsy (31576) performed separately from esophageal biopsy in same TNE session; verify NCCI first |
| -22 | Increased procedural complexity | Severe nasal obstruction requiring modified approach; multiple complex biopsy targets; prior esophageal surgery distorting anatomy; significantly increased procedure time; requires specific documentation |
| -52 | Reduced services | TNE initiated and partial esophageal examination performed but biopsy not ultimately obtainable due to patient intolerance, UES spasm, or scope/forceps failure; consider downcode to 43197 + 52 if no esophageal tissue obtained |
| -53 | Discontinued procedure | Procedure terminated after initiation due to significant threat to patient well-being (vasovagal, laryngospasm, epistaxis, severe patient distress) before biopsy obtained |
| -73 | Discontinued outpatient procedure prior to anesthesia | ASC setting — procedure discontinued before anesthesia administered |
| -74 | Discontinued outpatient procedure after anesthesia | ASC setting — procedure discontinued after anesthesia initiated |
| -76 | Repeat procedure by same physician | Same 43198 repeated by same physician same day — e.g., repeat TNE with biopsy after initial specimen inadequate or lost |
| -77 | Repeat procedure by different physician | Same 43198 performed by different physician same day |
| -78 | Return to OR/procedure suite for related procedure during global period | Re-examination with biopsy for related indication within 0-day global — rarely applicable given 0-day global; may apply within surgical package if 43198 is part of a bundled global |
| -79 | Unrelated procedure during postoperative period | Unrelated procedure within global period of a concurrent surgical service |
| -GC | Teaching physician service | Resident performed procedure under direct supervision of teaching physician |
| -GR | Rural health clinic | Service performed at a rural health clinic |
If a TNE is attempted with biopsy planned, but during the procedure:
- Esophagus reached, mucosal abnormality found, but biopsy NOT obtained (forceps malfunction, patient withdrawal refusal mid-procedure) → Bill 43197 (diagnostic only — accurately describes what was accomplished) — do NOT bill 43198 + 52
- Esophagus reached, biopsy attempted but specimen inadequate/no tissue obtained → Bill 43198 + modifier 52 with documentation of attempt and failure
- Esophagus not reached at all (UES spasm, inability to pass scope past nasopharynx) → Bill 43197 + modifier 52 documenting the extent of visualization achieved
The guiding principle: code what was actually performed and accomplished, with modifiers to accurately describe service reduction.
🩺 ICD-10-CM Diagnoses Commonly Paired with 43198
Barrett’s Esophagus — Primary 43198 Indication
| ICD-10-CM | Description | HCC? |
|---|---|---|
| K22.70 | Barrett’s esophagus without dysplasia | ❌ |
| K22.710 | Barrett’s esophagus with low-grade dysplasia | ❌ |
| K22.711 | Barrett’s esophagus with high-grade dysplasia | ❌ |
| K22.719 | Barrett’s esophagus with dysplasia, unspecified | ❌ |
Barrett's Esophagus — Code to the Highest Level of Documented Dysplasia
Barrett’s esophagus coding requires histopathologic confirmation from the biopsy — do not code dysplasia based solely on endoscopic appearance. The correct code hierarchy:
- Code the most advanced dysplasia documented on pathology from the current or most recent biopsy session
- When 43198 is the surveillance procedure — update the Barrett’s code based on current biopsy results when available
- If biopsying for Barrett’s surveillance and results are pending at time of coding — code the known Barrett’s diagnosis (e.g., K22.70 if previously confirmed non-dysplastic) with the understanding that the code may need updating when pathology returns
K22.711 (high-grade dysplasia) is a significant clinical finding — it triggers referral for ablative therapy (RFA — 43228) or esophagectomy, and should prompt concurrent staging evaluation (EUS — 43232). Ensure this diagnosis is accurately captured as it influences treatment pathway and reimbursement intensity.
GERD and Reflux Esophagitis
| ICD-10-CM | Description | HCC? |
|---|---|---|
| K21.0 | GERD with esophagitis | ❌ |
| K21.00 | GERD with esophagitis, without bleeding | ❌ |
| K21.01 | GERD with esophagitis, with bleeding | ❌ |
| K21.9 | GERD without esophagitis | ❌ |
Reflux Esophagitis — Biopsy to Exclude Complications
When 43198 is performed for refractory reflux esophagitis — erosive esophagitis not responding to PPI therapy — biopsy serves to:
- Exclude eosinophilic esophagitis (EoE) mimicking GERD
- Rule out infectious esophagitis (Candida, CMV, HSV) particularly in immunocompromised patients
- Exclude early Barrett’s metaplasia at the GEJ
- Confirm erosive esophagitis grade histologically
Code the specific GERD subtype based on the combination of clinical presentation and endoscopic/histopathologic findings. If esophagitis is confirmed → K21.00 or K21.01; if esophageal mucosa is normal despite symptoms → K21.9.
Eosinophilic Esophagitis (EoE)
| ICD-10-CM | Description | HCC? |
|---|---|---|
| K20.0 | Eosinophilic esophagitis | ❌ |
| K20.80 | Other esophagitis without bleeding | ❌ |
| K20.81 | Other esophagitis with bleeding | ❌ |
| K20.90 | Esophagitis, unspecified, without bleeding | ❌ |
| K20.91 | Esophagitis, unspecified, with bleeding | ❌ |
EoE — The Fastest-Growing 43198 Indication
Eosinophilic esophagitis (EoE) is now one of the most common indications for esophageal biopsy in both pediatric and adult patients. Key coding and clinical points for 43198 in the EoE context:
Diagnosis requires biopsy — EoE cannot be definitively coded without histopathologic confirmation (≥15 eosinophils/HPF on at least one biopsy level). Code K20.0 only after biopsy confirmation.
Systematic biopsy protocol for EoE diagnosis — Biopsies from at least two esophageal levels (proximal and distal) are recommended:
- Distal esophagus (5 cm above GEJ)
- Proximal esophagus (15–20 cm above GEJ)
- Mid-esophagus optional
All biopsies from one TNE session = one unit of 43198 regardless of number of levels biopsied.
EoE treatment monitoring via 43198 — Repeat biopsy after 8–12 weeks of PPI therapy or swallowed topical steroid treatment to confirm eosinophil count reduction. Code K20.0 if still active; revise if resolution documented.
ICD-10-CM specificity — K20.0 is the specific EoE code introduced in FY2020. Do not use K20.90 (esophagitis NOS) when EoE is confirmed — K20.0 provides greater clinical specificity.
Esophageal Malignancy
| ICD-10-CM | Description | HCC? |
|---|---|---|
| C15.3 | Malignant neoplasm of upper third of esophagus | ✅ HCC 11 |
| C15.4 | Malignant neoplasm of middle third of esophagus | ✅ HCC 11 |
| C15.5 | Malignant neoplasm of lower third of esophagus | ✅ HCC 11 |
| C15.8 | Malignant neoplasm of overlapping sites of esophagus | ✅ HCC 11 |
| C15.9 | Malignant neoplasm of esophagus, unspecified | ✅ HCC 11 |
| Z85.01 | Personal history of malignant neoplasm of esophagus | ❌ |
Esophageal Cancer — HCC Capture and Active vs. History
All esophageal malignancy codes (C15.3–C15.9) carry HCC 11 — a significant risk-adjustment driver in Medicare Advantage and value-based care. When 43198 is performed for evaluation of suspected malignancy or biopsy of a known/suspected esophageal cancer:
- Use active malignancy code (C15.x) if cancer is confirmed, active, or being evaluated/treated
- Use Z85.01 (personal history) only if prior esophageal cancer is in complete remission with no evidence of disease
- Do not code C15.x based on endoscopic appearance alone — wait for biopsy confirmation unless the pathology is already known from a prior biopsy at a different encounter
- When biopsy is taken at 43198 to confirm suspected malignancy, code the indication (suspected malignancy → R22.x or Z12.89 or the presenting symptom) until pathology returns; then update to confirmed malignancy code
Esophageal Carcinoma In Situ
| ICD-10-CM | Description | HCC? |
|---|---|---|
| D00.1 | Carcinoma in situ of esophagus | ❌ |
Carcinoma In Situ — High-Grade Dysplasia Spectrum
D00.1 (carcinoma in situ of esophagus) is used when pathology returns high-grade dysplasia/intramucosal carcinoma that does not meet criteria for invasive malignancy but exceeds the Barrett’s high-grade dysplasia threshold. Some pathologists use this term interchangeably with high-grade dysplasia — coordinate with your pathologist and physician documentation to determine whether D00.1 or K22.711 is the most accurate code for the specific histopathologic finding.
Esophageal Motility and Structural Disorders
| ICD-10-CM | Description | HCC? |
|---|---|---|
| K22.0 | Achalasia of cardia | ❌ |
| K22.1 | Ulcer of esophagus | ❌ |
| K22.10 | Ulcer of esophagus without bleeding | ❌ |
| K22.11 | Ulcer of esophagus with bleeding | ❌ |
| K22.2 | Esophageal obstruction | ❌ |
| K22.4 | Dyskinesia of esophagus | ❌ |
| K22.5 | Diverticulum of esophagus, acquired | ❌ |
| K22.6 | Gastro-esophageal laceration-hemorrhage syndrome | ❌ |
| K22.89 | Other specified disease of esophagus | ❌ |
| K22.9 | Disease of esophagus, unspecified | ❌ |
Dysphagia
| ICD-10-CM | Description | HCC? |
|---|---|---|
| R13.10 | Dysphagia, unspecified | ❌ |
| R13.11 | Dysphagia, oral phase | ❌ |
| R13.12 | Dysphagia, oropharyngeal phase | ❌ |
| R13.13 | Dysphagia, pharyngeal phase | ❌ |
| R13.14 | Dysphagia, pharyngoesophageal phase | ❌ |
| R13.19 | Other dysphagia | ❌ |
Dysphagia Code Selection — Update After Biopsy Results
When 43198 is performed for dysphagia evaluation and biopsy is taken of a structural finding (stricture, mass, or abnormal mucosa), code the dysphagia code (R13.1x) as the principal diagnosis at the time of the procedure if the etiology is not yet confirmed. Update to the specific etiology code (e.g., K22.2 for obstruction, C15.5 for malignancy, K20.0 for EoE) when biopsy pathology is received and reviewed with the patient.
Infectious Esophagitis
| ICD-10-CM | Description | HCC? |
|---|---|---|
| B37.81 | Candidal esophagitis | ❌ |
| B00.89 | Other herpesviral infection (herpetic esophagitis) | ❌ |
| B25.89 | Other cytomegaloviral diseases (CMV esophagitis) | ❌ |
| B20 | HIV disease | ✅ HCC 1 |
| D84.9 | Immunodeficiency, unspecified | ✅ HCC 47 |
| Z94.0 | Kidney transplant status | ❌ |
| Z94.1 | Heart transplant status | ❌ |
| Z79.899 | Other long-term (current) drug therapy (immunosuppressants) | ❌ |
Infectious Esophagitis — Sequence Correctly
When 43198 is performed for infectious esophagitis biopsy:
- Code the specific infection (B37.81, B00.89, B25.89) as the principal diagnosis when biopsy confirms the organism
- Code the underlying immunocompromised state as an additional diagnosis (B20 for HIV — HCC 1; Z94.x for transplant status)
- B20 (HIV disease) carries HCC 1 — the highest-tier HCC category in the CMS HCC model. This must be captured at every encounter where HIV is documented and managed, including TNE visits for HIV-related esophagitis
Laryngopharyngeal Reflux and Laryngeal Findings
| ICD-10-CM | Description | HCC? |
|---|---|---|
| K21.9 | GERD without esophagitis (LPR coded here) | ❌ |
| J38.00 | Paralysis of vocal cords and larynx, unspecified | ❌ |
| J38.01 | Paralysis of vocal cords and larynx, unilateral | ❌ |
| J38.1 | Polyp of vocal cord and larynx | ❌ |
| J38.2 | Nodules of vocal cords | ❌ |
| J38.3 | Other diseases of vocal cords | ❌ |
| J38.4 | Edema of larynx | ❌ |
| J37.0 | Chronic laryngitis | ❌ |
| R49.0 | Dysphonia | ❌ |
Esophageal Inlet Patch / Heterotopic Gastric Mucosa
| ICD-10-CM | Description | HCC? |
|---|---|---|
| Q39.6 | Congenital diverticulum of esophagus | ❌ |
| K22.89 | Other specified disease of esophagus (inlet patch — use when no more specific code available) | ❌ |
| Q39.8 | Other specified congenital malformations of esophagus | ❌ |
Esophageal Inlet Patch — Emerging TNE Indication
The esophageal inlet patch (heterotopic gastric mucosa in the proximal esophagus, typically at the level of the upper esophageal sphincter, 15–20 cm from the nares) is increasingly recognized as a cause of globus pharyngeus, throat clearing, and upper esophageal symptoms. TNE with biopsy (43198) is the ideal diagnostic procedure — the proximal esophageal location is easily visualized transnasally, and biopsy confirms gastric-type mucosa. ICD-10-CM lacks a specific inlet patch code — code K22.89 (other specified disease of esophagus) and document “heterotopic gastric mucosa / inlet patch” in the diagnostic statement.
Post-Ablation Barrett’s Surveillance
| ICD-10-CM | Description | HCC? |
|---|---|---|
| K22.70 | Barrett’s esophagus without dysplasia (post-ablation, if confirmed eradicated) | ❌ |
| Z09 | Encounter for follow-up examination after completed treatment (non-malignant condition) | ❌ |
| Z87.19 | Personal history of other diseases of digestive system | ❌ |
Post-RFA Barrett's Surveillance — Code Selection
After radiofrequency ablation (RFA) or cryotherapy for Barrett’s esophagus, TNE with biopsy (43198) is used to confirm eradication of intestinal metaplasia (CE-IM — complete eradication of intestinal metaplasia). Coding:
- If complete eradication confirmed on current biopsy → Z87.19 (personal history of digestive disease) with Z09 (follow-up encounter)
- If residual Barrett’s without dysplasia on post-ablation biopsy → K22.70
- If recurrent dysplasia → K22.710 or K22.711 as appropriate
- The specific post-ablation surveillance indication is typically documented as the clinical indication on the procedure request — ensure coding aligns with confirmed pathology results
Complicating Conditions and Comorbidities
| ICD-10-CM | Description | HCC? |
|---|---|---|
| E11.9 | Type 2 diabetes mellitus without complications | ✅ HCC 19 |
| E66.01 | Morbid (severe) obesity due to excess calories | ❌ |
| B20 | HIV disease | ✅ HCC 1 |
| C90.00 | Multiple myeloma, not having achieved remission | ✅ HCC 10 |
| D84.9 | Immunodeficiency, unspecified | ✅ HCC 47 |
| F10.20 | Alcohol use disorder, moderate | ❌ |
| J34.2 | Deviated nasal septum (affecting TNE approach) | ❌ |
🏨 MS-DRG Mapping
43198 — Primarily an Outpatient Procedure
Like 43197, 43198 is overwhelmingly performed in the office or ambulatory outpatient setting. Inpatient performance is uncommon but occurs when 43198 is part of an inpatient workup for esophageal disease, malignancy staging, or post-surgical evaluation. When performed inpatient, the ICD-10-PCS equivalent drives DRG assignment.
Esophageal / GI DRGs (When Performed Inpatient)
| MS-DRG | Description | Approx. Relative Weight |
|---|---|---|
| 391 | Esophagitis, Gastroenteritis, and Misc. Digestive Disorders w/ MCC | ~1.8–2.2 |
| 392 | Esophagitis, Gastroenteritis, and Misc. Digestive Disorders w/o MCC | ~1.0–1.3 |
| 374 | Digestive Malignancy w/ MCC | ~2.8–3.2 |
| 375 | Digestive Malignancy w/ CC | ~1.7–2.1 |
| 376 | Digestive Malignancy w/o CC/MCC | ~1.0–1.3 |
ENT / Head & Neck DRGs (When Performed During ENT Admission)
| MS-DRG | Description | Approx. Relative Weight |
|---|---|---|
| 154 | Other Ear, Nose, Mouth & Throat OR Procedures w/ MCC | ~3.1–3.6 |
| 155 | Other Ear, Nose, Mouth & Throat OR Procedures w/ CC | ~2.0–2.4 |
| 156 | Other Ear, Nose, Mouth & Throat OR Procedures w/o CC/MCC | ~1.4–1.7 |
DRG Optimization When 43198 Is Performed Inpatient
When 43198 is performed during an inpatient admission, the biopsy finding may itself introduce a new diagnosis that changes DRG assignment. For example:
- Pre-biopsy admission diagnosis: R13.10 (dysphagia) → low-weight DRG
- Post-biopsy confirmed: C15.5 (esophageal malignancy, lower third) (HCC 11) → escalates to Digestive Malignancy DRG 374 (MCC-tier if malignancy itself drives higher weight)
Ensure that diagnoses confirmed by pathology during the inpatient stay are captured in the final coded discharge — do not limit coding to pre-procedure working diagnoses. Per ICD-10-CM Official Guidelines, conditions confirmed by diagnostic testing during the inpatient stay are coded even if not present on admission (POA = N for such diagnoses).
🌳 CPT Code Tree — Transnasal Esophagoscopy & Esophagoscopy Family
Transnasal Esophagoscopy — 43197/43198 Family
├── 43197 — Transnasal esophagoscopy; DIAGNOSTIC
│ └── No forceps biopsy; brushing/washing included; no tissue histopathology
│
└── 43198 ← TRANSNASAL ESOPHAGOSCOPY; WITH BIOPSY (THIS CODE)
└── Forceps tissue biopsy — single or multiple specimens; histopathology generated
└── Brushing/washing also bundled when performed
Rigid Transoral Esophagoscopy (OR-based)
├── 43191 — Rigid esophagoscopy; diagnostic
├── 43192 — Rigid esophagoscopy; with biopsy
├── 43193 — Rigid esophagoscopy; with brushing or washing
├── 43194 — Rigid esophagoscopy; with removal of foreign body
├── 43195 — Rigid esophagoscopy; with balloon dilation
└── 43196 — Rigid esophagoscopy; with insertion of guide wire
Flexible Transoral Esophagoscopy — Diagnostic and Therapeutic
├── 43200 — Flexible transoral esophagoscopy; diagnostic
├── 43202 — Flexible esophagoscopy; with biopsy ← Transoral equivalent of 43198
├── 43204 — Flexible esophagoscopy; with injection of submucosal substance
├── 43205 — Flexible esophagoscopy; with band ligation of varices
├── 43206 — Flexible esophagoscopy; with optical endomicroscopy
├── 43210 — Esophagoscopy, flexible; with esophagogastric fundoplasty
├── 43212 — Flexible esophagoscopy; with stent placement
├── 43213 — Flexible esophagoscopy; with removal of esophageal stent
├── 43214 — Flexible esophagoscopy; with dilation of esophagus
├── 43215 — Flexible esophagoscopy; with removal of foreign body
├── 43216 — Flexible esophagoscopy; with endoscopic mucosal resection (EMR)
├── 43217 — Flexible esophagoscopy; with polypectomy
├── 43220 — Flexible esophagoscopy; with balloon dilation (less than 30 mm)
├── 43226 — Flexible esophagoscopy; with dilation, rigid dilator
└── 43228 — Flexible esophagoscopy; with ablation (RFA, cryotherapy)
Upper GI Endoscopy — EGD (Esophagus + Stomach + Duodenum)
├── 43235 — EGD; diagnostic
├── 43239 — EGD; with biopsy ← Comprehensive transoral equivalent for esophagus + stomach
├── 43240 — EGD; with transmural drainage
├── 43242 — EGD; with transendoscopic ultrasound-guided FNA/biopsy
├── 43249 — EGD; with dilation of esophagus up to 30 mm
├── 43252 — EGD; with optical endomicroscopy
├── 43254 — EGD; with endoscopic mucosal resection (EMR)
└── 43257 — EGD; with delivery of thermal energy to LES/gastric cardia
Laryngoscopy — Related ENT Procedures (Verify NCCI with 43198)
├── 31575 — Laryngoscopy, flexible; diagnostic *(NCCI bundled with 43198)*
├── 31576 — Laryngoscopy, flexible; with biopsy *(separately reportable with [[-59]] — verify)*
├── 31577 — Laryngoscopy, flexible; with removal of foreign body
├── 31578 — Laryngoscopy, flexible; with removal of lesion
└── 31579 — Laryngoscopy, flexible; with stroboscopy
Swallowing Function
├── 92612 — FEES; physician examination without interpretation
└── 92613 — FEES; with interpretation and report
Esophageal Function Studies
├── 91010 — Esophageal motility study (manometry)
├── 91013 — Esophageal motility with Mecholyl or similar
├── 91034 — Esophageal pH electrode placement (24-hour monitoring)
├── 91035 — Esophageal pH electrode with pH and impedance monitoring
└── 91038 — Esophageal function test; prolonged pH monitoring
Pathology — Separately Billed by Pathologist from 43198 Specimens
├── 88304 — Level III surgical pathology *(small biopsy — limited)*
├── 88305 — Level IV surgical pathology *(standard esophageal biopsy — most common)*
├── 88307 — Level V surgical pathology *(complex/malignancy with special stains)*
├── 88342 — Immunohistochemistry *(p53, CDX2, p16, viral IHC)*
└── 88104 — Cytopathology *(if brushing cytology also performed)*
🗂️ ICD-10-PCS Context (Inpatient Coding)
Inpatient Coder Note (CIC Relevance)
In the inpatient acute care setting, 43198 is not assigned. All procedures are coded in ICD-10-PCS. Transnasal esophagoscopy with biopsy maps to the Excision root operation — cutting out a portion of the esophageal body for diagnostic purposes — with the Diagnostic qualifier (X).
ICD-10-PCS Root Operation — Excision with Diagnostic Qualifier
Esophageal Biopsy via Transnasal Endoscope:
| Axis | Value |
|---|---|
| Section | 0 – Medical & Surgical |
| Body System | D – Gastrointestinal System |
| Root Operation | B – Excision (cutting out or off, without replacement, a portion of a body part) |
| Body Part | 5 – Esophagus |
| Approach | 8 – Via Natural or Artificial Opening Endoscopic |
| Device | Z – No Device |
| Qualifier | X – Diagnostic (biopsy for diagnostic purposes — not therapeutic excision) |
Excision (B) + Qualifier X — The 43198 Equivalent in PCS
The Diagnostic qualifier (X) is the critical PCS element that distinguishes a biopsy (diagnostic excision → 43198 equivalent) from a therapeutic excision (e.g., EMR, polypectomy). When the procedure is a biopsy taken to establish diagnosis, qualifier X – Diagnostic is always appended. This qualifier signals to the DRG grouper and clinical documentation reviewers that the tissue removal was for diagnosis, not treatment.
Multiple Biopsy Sites — PCS Coding
When biopsies are obtained from multiple distinct esophageal locations in a single endoscopic session, ICD-10-PCS coding practice varies by facility:
| Scenario | PCS Coding Approach |
|---|---|
| Biopsies from same body part (esophagus, multiple levels) | Single Excision code for Esophagus — multiple specimens from same body part designation coded once per ICD-10-PCS guidelines |
| Biopsy of esophagus AND larynx (different body parts) | Two separate Excision codes — one for Esophagus (D, body part 5) and one for the laryngeal body part (e.g., body system C — Mouth and Throat) |
PCS Guideline B3.2a — Multiple Procedures Same Body Part
Per ICD-10-PCS Official Guideline B3.2a: when the same root operation is performed on the same body part multiple times during the same operative episode, report the root operation only once. Therefore, biopsies at three different esophageal levels (all body part = Esophagus) = one Excision, Esophagus, Endoscopic, X – Diagnostic code.
Comparison — ICD-10-PCS for 43197 vs. 43198
| CPT | PCS Root Operation | Qualifier | Rationale |
|---|---|---|---|
| 43197 | J – Inspection | Z – No Qualifier | Visualization only — no tissue removed |
| 43198 | B – Excision | X – Diagnostic | Tissue removed for biopsy — diagnostic purpose |
| 43202 | B – Excision | X – Diagnostic | Transoral biopsy — same PCS structure |
| 43228 (RFA) | D – Extraction or 5 – Destruction | Z – No Qualifier | Therapeutic destruction — not diagnostic |
Brushing Cytology + Biopsy in Same Session — PCS
When both brushing (cytology) and forceps biopsy are performed in the same TNE session, only the Excision (biopsy) code is assigned in ICD-10-PCS — the brushing/washing is considered integral to the biopsy session and is not separately coded in ICD-10-PCS. This aligns with the CPT bundling principle where 43197 (which includes brushing) is subsumed into 43198 when biopsy is also performed.
📝 Coding Examples
Example 1 — Suspected Barrett’s Esophagus, First Biopsy Confirmation
Clinical Scenario: 58-year-old male with 15-year history of GERD, now on daily PPI. Physician performs office-based TNE using 5.4 mm flexible transnasal scope with topical anesthesia. At 36 cm, salmon-pink columnar-appearing mucosa extends 3 cm above the GEJ (Z-line at 36 cm; GEJ at 39 cm). Biopsy forceps introduced; four-quadrant biopsies taken at 36, 37, and 38 cm (12 total specimens). Pathology returns: intestinal metaplasia with goblet cells — no dysplasia. Barrett’s esophagus confirmed.
CPT Code:
- 43198 — Transnasal esophagoscopy with biopsy, single or multiple (12 specimens — one unit)
ICD-10-CM:
- K21.9 — GERD without esophagitis (pre-biopsy indication; update to K22.70 when pathology confirmed)
- K22.70 — Barrett’s esophagus without dysplasia (post-pathology — update coding when result received)
Coding Timing — Pre- vs. Post-Pathology
At the time of the procedure, code the indication (K21.9 or R13.10 or symptom code). When pathology results confirm the diagnosis, update the encounter coding to the confirmed diagnosis (K22.70). In outpatient coding, code the confirmed diagnosis when results are available — do not code “suspected” conditions in the outpatient setting (per ICD-10-CM outpatient guidelines).
Example 2 — EoE Diagnosis Workup (Proximal and Distal Biopsies)
Clinical Scenario: 28-year-old male with 6-month history of solid food dysphagia, three episodes of food impaction, and intermittent chest pain. Allergic history to multiple environmental allergens and tree nuts. Office TNE performed: esophageal lumen shows linear furrows throughout; fixed concentric rings (trachealization) of the mid-esophagus; whitish exudate. Biopsies obtained from proximal esophagus (22 cm — 3 specimens) and distal esophagus (35 cm — 3 specimens). Pathology: ≥25 eosinophils/HPF at both levels. EoE confirmed. Patient placed on swallowed budesonide.
CPT Code:
- 43198 — Transnasal esophagoscopy with biopsy, single or multiple (6 total specimens — one unit)
ICD-10-CM:
- K20.0 — Eosinophilic esophagitis (confirmed on biopsy — code after pathology review)
- R13.14 — Dysphagia, pharyngoesophageal phase (additional — presenting symptom)
- J30.9 — Allergic rhinitis, unspecified (additional — atopic background)
Example 3 — Barrett’s Surveillance with High-Grade Dysplasia Identified
Clinical Scenario: 65-year-old female with known Barrett’s esophagus (3 cm, previously non-dysplastic). Returns for annual surveillance TNE. Seattle protocol biopsy performed — 4-quadrant biopsies every 1 cm throughout 3 cm segment plus GEJ (16 specimens total); targeted biopsy of one nodular area at 37 cm (2 additional specimens — 18 total). Pathology: high-grade dysplasia confirmed at 37 cm nodule; low-grade dysplasia in one quadrant at 36 cm. Patient referred for RFA ablation (43228) and EUS staging.
CPT Code:
- 43198 — Transnasal esophagoscopy with biopsy (18 specimens — one unit)
ICD-10-CM:
- K22.711 — Barrett’s esophagus with high-grade dysplasia (principal — most advanced dysplasia confirmed)
- (Prior K22.70 updated to K22.711 based on current biopsy results)
Example 4 — TNE with Biopsy for Esophageal Mass (Suspected Malignancy)
Clinical Scenario: 71-year-old male with 3-month progressive dysphagia to solids and 12 lbs weight loss. CT chest shows irregular thickening of the distal esophagus. Office TNE performed: irregular, friable, fungating mucosal mass at 32–38 cm with near-complete luminal obstruction. Scope narrowly passes lesion. Three biopsies obtained from the mass periphery (forceps). Pathology: moderately differentiated squamous cell carcinoma of the esophagus.
CPT Code:
- 43198 — Transnasal esophagoscopy with biopsy (3 specimens — one unit)
ICD-10-CM:
- C15.4 — Malignant neoplasm of middle third of esophagus (principal — location of mass at 32–38 cm) (HCC 11)
- R13.10 — Dysphagia, unspecified (additional — presenting symptom leading to procedure)
- R63.4 — Abnormal weight loss (additional — 12 lbs weight loss documented)
Malignancy Confirmed on Biopsy — Code After Pathology
Do NOT code C15.4 at the time of the procedure based on endoscopic appearance alone. Code the presenting symptom (R13.10, R63.4) at the procedure encounter. When pathology confirms malignancy, update the diagnosis to C15.4 at the follow-up encounter or on the procedure note addendum when results are reconciled. In the inpatient setting, if biopsy confirms malignancy during the same admission, code the confirmed malignancy as the principal diagnosis per ICD-10-CM inpatient coding guidelines.
Example 5 — Candidal Esophagitis in Immunocompromised Patient (HIV)
Clinical Scenario: 45-year-old male with HIV (CD4 count 89 cells/µL, not on ART) presents with 2-week odynophagia and difficulty swallowing liquids. TNE: whitish plaques adherent to esophageal mucosa from 20 to 35 cm, friable when touched. Three biopsies obtained. Pathology: PAS stain positive for yeast and pseudohyphae consistent with Candida albicans esophagitis.
CPT Code:
- 43198 — Transnasal esophagoscopy with biopsy (3 specimens — one unit)
ICD-10-CM:
- B37.81 — Candidal esophagitis (principal — biopsy confirmed)
- B20 — HIV disease (additional — underlying immunosuppression) (HCC 1)
- R13.10 — Dysphagia, unspecified (additional — presenting symptom)
Example 6 — Post-RFA Barrett’s Surveillance (Eradication Confirmed)
Clinical Scenario: 60-year-old male, 12 months post-RFA for low-grade dysplastic Barrett’s esophagus (2 cm segment). Returns for post-ablation surveillance TNE. Endoscopic appearance: squamous re-epithelialization of the treatment zone; no visible columnar mucosa; Z-line at GEJ level. Four-quadrant biopsies at the neo-squamocolumnar junction (8 specimens). Pathology: squamous epithelium, no intestinal metaplasia, no dysplasia — complete eradication of intestinal metaplasia (CE-IM) confirmed.
CPT Code:
- 43198 — Transnasal esophagoscopy with biopsy (8 specimens — one unit)
ICD-10-CM:
- Z09 — Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm (post-RFA surveillance)
- Z87.19 — Personal history of other diseases of digestive system (prior Barrett’s — now eradicated)
Example 7 — Combined TNE with Biopsy + Separately Documented Laryngoscopy
Clinical Scenario: 52-year-old female with two distinct referral indications: (1) long-standing dysphonia with right vocal cord lesion seen on prior mirror laryngoscopy (separate laryngeal biopsy needed) and (2) progressive dysphagia with suspected Barrett’s esophagus (esophageal biopsy needed). ENT performs: complete flexible laryngoscopy documenting right vocal cord lesion — targeted biopsy obtained from right cord lesion. Then TNE performed — Barrett’s segment identified at GEJ; four-quadrant biopsies taken. Two entirely distinct procedures performed with separate indications, separate anatomical sites, separate specimens.
CPT Codes:
- 43198 — Transnasal esophagoscopy with biopsy (Barrett’s surveillance — esophageal specimens)
- 31576 — Flexible laryngoscopy with biopsy (right vocal cord lesion — laryngeal specimen) (modifier 59 — distinct anatomical site, distinct indication, distinct specimen; verify NCCI)
ICD-10-CM:
- K21.9 — GERD without esophagitis (esophageal/TNE indication — update to K22.70 when Barrett’s confirmed)
- J38.1 — Polyp of vocal cord and larynx (laryngoscopy indication — right cord lesion)
- R49.0 — Dysphonia (additional — presenting laryngeal symptom)
This combination is subject to NCCI scrutiny. For both codes to survive audit:
- The procedure report must contain two completely separate sections — one for the laryngoscopy with biopsy and one for the transnasal esophagoscopy with biopsy
- Each section must document independent indications, separate target tissues, separate specimen jars, and separate clinical findings
- The laryngeal biopsy must be clearly distinct from any laryngeal visualization during TNE scope passage
- Modifier -59 on 31576 with documentation of distinct anatomical sites (larynx vs. esophagus)
- Some payers will still deny 31576 — verify payer-specific NCCI edits before submitting
Example 8 — Reduced Service — Biopsy Attempted but Specimen Inadequate
Clinical Scenario: 68-year-old male with known Barrett’s esophagus returns for surveillance TNE with planned biopsy. Scope successfully advanced to GEJ — Barrett’s segment visualized. Biopsy forceps introduced; two attempts made but specimens obtained were crush artifacts — inadequate for histopathologic interpretation. Patient tolerated procedure but was increasingly uncomfortable; procedure terminated. Pathology report: “crush artifact — insufficient tissue for diagnosis.”
CPT Code:
- 43198 with modifier -52 — Transnasal esophagoscopy with biopsy; reduced services (biopsy attempted — specimens inadequate; histopathologic diagnosis not achieved)
ICD-10-CM:
- K22.70 — Barrett’s esophagus without dysplasia (surveillance indication — known prior diagnosis)
⚠️ Common Coding Pitfalls
- 43197 vs. 43198 — the single most critical decision: If any forceps biopsy was obtained → 43198 always. If only brushing/washing → 43197. Read the procedure report’s biopsy section before assigning either code. The words “biopsy,” “forceps,” “specimens to pathology,” or “tissue sampling” in the report = 43198.
- Never bill 43197 + 43198 in the same session: 43197 is completely subsumed into 43198 when biopsy is performed. Billing both is a NCCI violation and a duplicate billing error.
- Multiple units of 43198 — never appropriate: Regardless of how many biopsy specimens are obtained (1 or 16), 43198 is always billed as one unit in a single session. The code descriptor “single or multiple” is explicit. Multiple units will be denied as NCCI violations.
- Code what was actually done — not what was planned: If biopsy was planned but not achieved (scope couldn’t advance, patient intolerant) → 43197 or 43197 + 52 depending on extent of examination. If biopsy was not planned but was taken due to unexpected finding → 43198. The plan is irrelevant; the service rendered determines the code.
- Pathology is not the endoscopist’s to bill: The 88305 surgical pathology evaluation is billed by the pathologist/laboratory — not by the endoscopist performing 43198. Do not include pathology codes on the endoscopist’s claim.
- Barrett’s coding without pathology confirmation: Do not code K22.710 or K22.711 (dysplastic Barrett’s) based on endoscopic appearance alone. These codes require histopathologic confirmation. Code the working diagnosis (symptom or K21.9) at the time of the procedure and update to the confirmed diagnosis when pathology returns.
- EoE — requires K20.0, not K20.90: When EoE is confirmed on biopsy, use the specific code K20.0 — not the generic esophagitis NOS code (K20.90). K20.0 was introduced specifically for EoE; its use demonstrates coding precision and supports appropriate clinical data capture.
- Inpatient coding: Never assign 43198 for an inpatient acute care stay. Use ICD-10-PCS: Excision (B), Esophagus, Via Natural Opening Endoscopic, Diagnostic (X). Failure to add the X qualifier (treating as therapeutic excision) misrepresents the procedure’s intent.
- Active vs. personal history malignancy: When 43198 confirms esophageal cancer, update to active malignancy code (C15.x) — not personal history (Z85.01). HCC capture depends on active code use.
- 43198 and separate laryngoscopy with biopsy (31576) — This combination is defensible when two genuinely separate procedures are performed for independent indications at distinct sites (larynx vs. esophagus). Document meticulously and verify NCCI before submitting.
- Non-facility billing requires actual office setting: Billing POS 11 for 43198 when the procedure is performed at a hospital outpatient or ASC location overstates the PE component and constitutes place-of-service fraud. Confirm that the procedure was actually performed in the physician’s office before using non-facility RVU.
📚 Brief Source References
AMA CPT Professional Edition 2025, codes 43197–43198 and esophagoscopy section guidelines and parenthetical notes CMS Medicare Physician Fee Schedule Final Rule 2025 – Work RVU, facility/non-facility PE RVU, and payment indicator files (www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched) CMS NCCI Policy Manual for Medicare Services, Chapter 8: Surgery – Digestive System, 2025 CMS MS-DRG Definitions Manual v41 FY2024 – DRGs 391–392, 374–376 ICD-10-PCS Official Guidelines for Coding and Reporting FY2025 – Section B3 Root Operations: Excision (B), Diagnostic Qualifier (X); Guideline B3.2a Multiple Procedures ICD-10-CM Official Guidelines for Coding and Reporting FY2025 – Section I.C.2 Neoplasms; Section I.C.11 Digestive System; Outpatient coding guidelines Section IV American College of Gastroenterology (ACG). Clinical Guidelines: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol 2022;117(4):559–587 Dellon ES, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis. Am J Gastroenterol 2013;108(5):679–692 Postma GN, Cohen JT, Belafsky PC, et al. Transnasal esophagoscopy: revisited (over 700 consecutive cases). Laryngoscope 2005;115(2):321–323 Amin MR, Postma GN, Johnson P, et al. Transnasal esophagoscopy: a position statement from the American Bronchoesophagological Association (ABEA). Otolaryngol Head Neck Surg 2008;138(4):411–414 AAPC CPC/CIC Study Guide – Surgery: Digestive System / Esophagoscopy chapter